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MAPKAP Kinase 2 (MK2)-Dependent
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Xuming Mao1, Hong Li1, Yasuyo Sano2, Matthias Gaestel3, Jin Mo Park2 and Aimee S. Payne1
Pemphigus vulgaris (PV) is an autoimmune blistering disease characterized by autoantibodies to the keratinocyte
adhesion protein desmoglein 3 (Dsg3). Previous studies suggest that PV pathogenesis involves p38 mitogen-
activated protein kinase-dependent and -independent pathways. However, p38 is a difficult protein to study and
therapeutically target because it has four isoforms and multiple downstream effectors. In this study, we identify
MAPKAP (mitogen-activated protein kinase-activated protein) kinase 2 (MK2) as a downstream effector of p38
signaling in PV and describe MK2-dependent and -independent mechanisms of blister formation using passive
transfer of human anti-Dsg IgG4 mAbs to neonatal mice. In human keratinocytes, PV mAbs activate MK2 in a
dose-dependent manner. MK2 is also activated in human pemphigus skin blisters, causing translocation of MK2
from the nucleus to the cytosol. Small-molecule inhibition of MK2 and silencing of MK2 expression block PV
mAb-induced Dsg3 endocytosis in human keratinocytes. In addition, small-molecule inhibition and genetic
deletion of p38a and MK2 inhibit spontaneous but not induced suprabasal blisters by PV mAbs in mouse passive
transfer models. Collectively, these data suggest that MK2 is a key downstream effector of p38 that can modulate
PV autoantibody pathogenicity. MK2 inhibition may be a valuable adjunctive therapy for control of pemphigus
blistering.
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INTRODUCTION
Pemphigus vulgaris (PV) is a potentially life-threatening
blistering disease caused by autoantibodies against desmo-
glein (Dsg) adhesion proteins. Pathogenic anti-Dsg antibodies
disrupt the assembly of Dsg into nascent desmosomes, result-
ing in desmosome disassembly and loss of intercellular
adhesion (Kitajima, 2002; Calkins et al., 2006; Cirillo et al.,
2006; Mao et al., 2009), evidenced histologically as
suprabasal acantholysis. Pathogenic serum IgG antibodies
bind calcium-sensitive conformational epitopes in the Dsg
extracellular amino-terminal domains, whereas nonpatho-
genic serum IgG binds nonconformational epitopes
throughout the extracellular domains (Amagai et al., 1992,
1995). Anti-Dsg mAbs that bind amino-terminal calcium-
sensitive epitopes and cause suprabasal acantholysis have
been identified from an active immune mouse model of
PV (Tsunoda et al., 2003), as well as human PV patients
(Payne et al., 2005; Yeh et al., 2006).
Skin adhesion is weakened even in the nonblistered skin of
pemphigus patients, as blisters can be induced in normal-
appearing skin by mechanical shear stress (known as the
Nikolsky sign). However, blisters also spontaneously occur in
pemphigus patients, even in the absence of mechanical shear
stress. Past studies have implicated diverse signaling pathways
in PV IgG-induced acantholysis, including p38 mitogen-
activated protein kinase (Berkowitz et al., 2005), rho family
GTPases (Waschke et al., 2006), protein kinase C (Sanchez-
Carpintero et al., 2004), and c-myc (Williamson et al., 2006),
among others (Sharma et al., 2007). Of these, a role for p38
has been the best established, with data from multiple
laboratories supporting necessary and sufficient roles for p38
in various aspects of pemphigus pathology. p38 is activated in
in vitro studies using PV serum IgG and mAbs (Berkowitz
et al., 2005; Kawasaki et al., 2006; Mao et al., 2011) and
in vivo in pemphigus patient skin (Berkowitz et al., 2007).
Exogenous p38 activation by oxidative stress or UV light
causes Dsg3 endocytosis in keratinocytes (Mao et al., 2011),
and p38 inhibition prevents pathological effects of PV serum
IgG and mAbs, including Dsg3 endocytosis and blistering in a
mouse passive transfer model (Berkowitz et al., 2006; Jolly
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et al., 2010; Mao et al., 2011). Recent studies by our
laboratory and others have proposed that steric hindrance of
Dsg3 adhesion (pathophysiologically equivalent to the
Nikolsky sign in patients) is signaling independent (Heupel
et al., 2008; Mao et al., 2011; Saito et al., 2012), whereas
spontaneous blistering is amplified by p38 signaling, which
may explain the therapeutic benefit of p38 inhibition in some
but not all PV models.
Currently, rapid control of pemphigus blistering is achieved
with corticosteroids, although the immunosuppressive and
hyperglycemic side effects of corticosteroids can cause com-
plications, making p38 a promising adjunctive target
for therapy in PV. However, p38 inhibitors have systemic
toxicities in humans (Goldstein et al., 2010), because of the
involvement of p38 in a broad range of cellular processes
and p38 inhibitor promiscuity, leading to off-target effects.
In addition, p38 has four isoforms (a, b, g, and d), which
complicate its study in biological systems. Therefore, we
sought to identify downstream effectors that regulate Dsg3
endocytosis and keratinocyte adhesion, which could be
more specific targets for therapeutic intervention. MAPKAP
(mitogen-activated protein kinase-activated protein) kinase 2
(MK2) regulates several cellular events downstream of p38
signaling, including tumor necrosis factor-a production and
cytoskeletal remodeling, both of which may contribute to PV
pathogenesis (Kotlyarov et al., 1999; Kayyali et al., 2002). In
this study, we identify MK2 as the major downstream
effector of p38 signaling in PV and describe MK2-dependent
and -independent mechanisms of blister formation.
RESULTS
MK2 is activated in lesional keratinocytes of pemphigus patients
To determine whether MK2 is activated in vivo in pemphigus,
we performed immunohistochemical analysis on skin biopsies
from four PV patients and two patients with the related
blistering disease, pemphigus foliaceus, to detect activated
(phospho-Thr222) MK2. Normal rabbit serum was a primary
antibody control (Figure 1, left panels). Activated MK2 was
observed in keratinocytes in the blister roof and base of PV
and pemphigus foliaceus patients (arrows). MK2 phosphoryla-
tion was not observed in PV nonlesional epidermis as
compared with normal human epidermis, although a slight
elevation of activated MK2 was observed in perilesional
keratinocytes (PV nonlesional, arrows).
Pathogenic anti-Dsg PV mAb activates MK2 in a dose-dependent
manner in PHEKs, causing translocation of MK2 from the
nucleus to the cytoplasm
Previously, we cloned human anti-Dsg single-chain variable
fragment mAbs from PV patients (Payne et al., 2005). Similar
to PV serum IgG, pathogenic single-chain variable fragment
mAbs cause Dsg3 endocytosis, dissociation of primary human
epidermal keratinocytes (PHEKs), and suprabasal blisters in
human skin explants and neonatal mice after passive transfer
(Payne et al., 2005; Mao et al., 2009). Pathogenic single-chain
variable fragment, IgG1, and IgG4 mAbs expressing the
same variable region activate p38 mitogen-activated protein
kinase in PHEKs with equivalent dose- dependency (Mao
et al., 2011). In contrast, nonpathogenic mAbs bind Dsg3 but
do not activate p38, cause Dsg endocytosis, or induce skin
blisters. We first determined whether a pathogenic IgG4 mAb
(recognizing both Dsg3 and Dsg1) that activates p38 and
causes skin blisters also activates MK2, by immunoblotting
PHEK lysates with an antibody specific for activated MK2,
using total MK2 protein as a loading control. Oxidative stress
(200mM H2O2) was a positive control and nonpathogenic
anti-Dsg3/1 IgG4 mAb was a negative control for stim-
ulating p38/MK2 signaling. Both the pathogenic mAb and
H2O2 activated MK2 in a dose-dependent manner (Figure 2a,
upper panels), with peak activation at 2 hours (Figure 2b).
Activation of p38 showed a similar pattern (Figure 2a, lower
panels).
Normal Normal PV1 PV3 PF1
PF2PV4PV2PV PV nonlesional
Phospho-MK2Rabbit serum
Figure 1. MAPKAP (mitogen-activated protein kinase-activated protein) kinase 2 (MK2) is activated in lesional skin keratinocytes from pemphigus vulgaris (PV)
and foliaceus (PF) patients. Activated MK2, demonstrated by immunohistochemical staining of pemphigus skin biopsy samples with an antibody specific for
phospho-MK2, was markedly increased in PV (PV1–4) and PF (PF1–2) lesional skin keratinocytes. No significant activation was observed in normal human skin or
PV nonlesional keratinocytes (arrows indicate focal activation in perilesional keratinocytes). Normal rabbit serum was used as an antibody-negative control.
Activated MK2 is primarily observed in the cytoplasm of keratinocytes (PV4 and PF1, inset). Bar¼100mm.
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Activation of MK2 causes its translocation from the nucleus
to the cytoplasm (Engel et al., 1998). We therefore perfor-
med subcellular fractionation of PHEKs after pathogenic mAb
stimulation. Before PV mAb treatment, MK2 is predominantly
located in the nucleus (Figure 2b, 0 hours). At 4–16 hours after
pathogenic PV mAb stimulation, MK2 protein shifts from the
nuclear to cytosolic fractions. Similarly, MK2, detected
by immunofluorescence staining, remains in the nucleus in
PHEKs treated with nonpathogenic mAb (Figure 2c). Upon
activation by pathogenic mAb or H2O2, MK2 translocates to
the cytoplasm. Similar findings are observed in vivo, as
activated MK2 is predominantly localized in the cytoplasm
of lesional keratinocytes in pemphigus patient skin (Figure 1,
PV4 and pemphigus foliaceus 1 insets).
Inhibition or knockdown of MK2 prevents PV mAb-mediated loss
of cell surface Dsg3 in human keratinocytes
If MK2 is the primary downstream effector of p38 signaling
in PV, then MK2 inhibition should prevent the pathological
effects of PV mAbs that are regulated by p38, including
Dsg3 endocytosis and loss of Dsg3 from the desmosomal
fraction of PHEKs (Jolly et al., 2010; Mao et al., 2011). We first
examined the efficacy and specificity of a pyrrolopyridinyl
MK2 inhibitor. The MK2 inhibitor (MK2I) decreases
phosphorylation of HSP27, a direct downstream target of
MK2, in a dose-dependent pattern (Figure 3a; total HSP27 as
a loading control), but does not affect the phosphorylation of
the upstream kinase p38. Treatment of PHEKs with the
p38 inhibitor SB202190 or MK2I decreases the loss of Dsg3
and desmoplakin from the Triton-insoluble fraction of PHEKs
(Figure 3b, upper panels). Consistent with these findings, MK2
inhibition prevents the pathogenic PV mAb-mediated loss of
cell surface Dsg3, similar to the effects of p38 inhibition
(Figure 3c).
To confirm the inhibitor studies, we used short hairpin RNA
(shRNA) to silence MK2 expression in HaCaT human
keratinocytes. MK2 protein levels were determined by immu-
noblotting, using histone H3 as a control. Compared with the
control shRNA-transfected cell line, MK2 expression was
almost completely silenced in the MK2 shRNA stable cell
line (Figure 4a, upper panel). p38 expression is also signifi-
cantly decreased in MK2 shRNA cells, which was unantici-
pated but consistent with prior reports indicating that
MK2 stabilizes p38 protein (Kotlyarov et al., 2002). MK2
knockdown was further confirmed by immunofluorescence
staining (Figure 4b). MK2 shRNA and control cells
were treated with phosphate-buffered saline, H2O2, or PV
pathogenic mAb, and the subcellular location of Dsg3
was determined by immunostaining. Both H2O2 and PV
mAb-induced loss of cell surface Dsg3 were decreased in
MK2 shRNA cells compared with control cells (Figure 4c),
consistent with the results of p38 and MK2 small-molecule
inhibition.
Genetic deletion or small-molecule inhibition of MK2 does not
inhibit induced blisters in a mouse passive transfer model
Mice can develop both Nikolsky and spontaneous suprabasal
blisters after passive transfer of PV mAbs. At 4–6 hours after
passive transfer, Nikolsky skin fragility occurs (induction of
blisters by mechanical shear stress). At 16–18 hours after
passive transfer, spontaneous blisters appear (in the absence
of applied mechanical shear stress). Previously, we demon-
strated that Nikolsky skin fragility is p38a -independent (Mao
et al., 2011). Similarly, mice with a genetic deletion of MK2
(Kotlyarov et al., 1999) are susceptible to induced suprabasal
blisters after passive transfer of pathogenic PV mAb
(Figure 5a). All six wild-type (WT) and four MK2-knockout
mice (MK2-KO) demonstrated gross blisters, with suprabasal
acantholysis and similar histology scores (Figure 5b and c).
Because MK2-deficient mice demonstrate decreased p38
levels, we also tested whether inhibition of MK2 signaling,
which does not affect p38 activation (Figure 3a), can block
induced blisters. We injected WT mice with PV mAbs 2 hours
after injection with 5mg of p38 inhibitor (SB202190) or
6.25mg of MK2I (doses determined by in vitro assays confirm-
ing sufficiency of kinase inhibition (Figure 3a) relative to
effective in vivo doses of p38 inhibitors (Berkowitz et al.,
2006). Similar to MK2-KO mice, WT mice pretreated with
DMSO or MK2I and then with pathogenic (P) mAb develop
blisters after mechanical shear stress (Figure 5d). All five
DMSOþ P and five MK2IþP mice demonstrated gross blis-
ters, again with suprabasal acantholysis and similar histology
scores (Figure 5e and f). Direct immunofluorescence analysis
confirmed mAb binding (data not shown).
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Figure 2. Pathogenic but not nonpathogenic pemphigus vulgaris (PV) mAbs
activate MAPKAP (mitogen-activated protein kinase-activated protein)
kinase 2 (MK2) in primary human keratinocytes. (a) Pathogenic (P) mAb
activates MK2 in a dose-dependent manner (treatment 2 hours), whereas
nonpathogenic (NP) mAb does not, similar to positive controls for p38
activation by P mAb and oxidative stress (H2O2). (b) Peak activation of MK2 by
50mg ml1 P mAb occurs at 2 hours. (c) MK2 translocates from the nucleus to
the cytosol after treatment of keratinocytes with P mAb. MK2 protein levels in
the cytosolic and nuclear fractions (cofractionation with b-tubulin and histone,
respectively) were detected by immunoblotting. (d) P mAb and H2O2, but not
NP mAb, cause MK2 translocation from the nucleus to the cytosol at 4 hours,
demonstrated by immunofluorescence. Bar¼20mm.
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Genetic deletion or inhibition of MK2 inhibits spontaneous
blister formation in a mouse passive transfer model
We next determined whether MK2 is required for spontaneous
blistering in the mouse passive transfer model. In contrast to
induced blisters, spontaneous blistering was significantly
reduced in MK2-KO mice compared with WT littermate
controls (Figure 6a). Of the 30 WT mice, 25 showed gross
blisters after passive transfer of pathogenic mAb as compared
with 4out of the 15 MK2-KO mice (P¼0.0005). Direct
immunofluorescence analysis of skin confirmed mAb binding
(data not shown). All 30 WT mice demonstrated suprabasal
acantholysis, with significantly increased histologic blistering
(Figure 6b and c). MK2-KO mice without gross blisters did not
demonstrate microscopic blisters. Unexpectedly, MK2-KO
mice with gross blisters demonstrated predominantly super-
ficial, with focal areas of suprabasal, acantholysis (Figure 6b,
bottom right). This phenotype was also observed in mice with
a K14-Cre-mediated deletion of p38a in the epidermis after
injection with pathogenic mAb (see Supplementary Text and
Supplementary Figure S1 online for full discussion). The extent
of suprabasal blistering in MK2-KO mice was significantly
reduced compared with WT mice (Figure 6c).
We then tested whether spontaneous blisters are dependent
on MK2 signaling. WT mice injected with pathogenic but
not nonpathogenic mAb developed spontaneous blisters
16–18 hours after passive transfer (Figure 6d). Pretreatment
with SB202190 (a p38 inhibitor) or MK2I inhibited blister
formation. Seven out of eight mice injected with pathogenic
mAb demonstrated gross blistering, whereas two out of eight
mice injected with MK2I and one out of four mice with
SB202190 and then pathogenic mAb blistered (Po0.05).
Histologic analysis confirmed inhibition of blistering
(Figure 6e and f), although focal suprabasal acantholysis was
observed on the edge of some tissue specimens, consistent
with Nikolsky skin fragility due to tissue processing.
Direct immunofluorescence confirmed binding of mAbs to
the keratinocyte cell surface (data not shown).
We attempted to evaluate whether PV serum IgG is similarly
blocked by MK2 deficiency or inhibition. However, two PV
serum IgG samples that caused suprabasal blisters in human
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Figure 3. MAPKAP (mitogen-activated protein kinase-activated protein) kinase 2 (MK2) inhibition blocks loss of cell surface desmoglein 3 (Dsg3) by
pathogenic (P) pemphigus vulgaris (PV) mAb. (a) Pretreatment of primary human epidermal keratinocytes (PHEKs) with an MK2-specific inhibitor (MK2I) for
2 hours, and then PV mAb for 2 hours, blocks phosphorylation of HSP27 but not p38 in a dose-dependent pattern. (b) MK2I rescues the loss of desmosomal
Dsg3 caused by P mAb. PHEKs were treated with DMSO, 2mM SB202190 (p38 inhibitor), or 2.5mg ml1 MK2I for 2 hours, followed by 50mg ml1 PV mAbs
(P or nonpathogenic (NP)) for 6 hours. Triton X-100–insoluble fractions were immunoblotted with antibodies as indicated. Data are representative of three
independent experiments. (c) P but not NP mAb (as in b) causes loss of cell surface Dsg3 (green), which is inhibited by SB202190 and MK2I. Bar¼ 20mm.
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skin explants did not cause suprabasal blisters in mice because
of lack of crossreactivity or low-affinity binding to mouse
compared with human Dsg3 (data not shown).
DISCUSSION
In this study, we describe signaling-dependent and -indepen-
dent models of blister formation in PV and identify MK2 as the
major downstream effector of p38-dependent pathology in PV.
Pathogenic PV autoantibodies activate MK2 in vivo in the
skin of PV patients and mice after passive transfer (Figure 1
and Supplementary Figure S1 online) and in vitro in PHEKs
(Figure 2a). MK2 is activated by phosphorylation of residue
Thr222 and Thr334 by p38. Phosphorylation of Thr334, which
regulates the nuclear localization and nuclear export signals of
MK2, results in translocation of MK2 from the nucleus to the
cytoplasm (Kotlyarov et al., 2002). Accordingly, MK2
translocates from the nucleus to cytoplasm in response to
pathogenic PV mAb (Figure 2) and is predominantly localized
in the cytoplasm of lesional keratinocytes in pemphigus
patient skin (Figure 1).
In addition, we demonstrate that MK2 inhibition, using both
small-molecule and genetic approaches, prevents loss of cell
surface Dsg3 (Figures 3 and 4) and spontaneous blister
formation in a mouse passive transfer PV model (Figure 6).
The specificity of MK2 small-molecule inhibition is supported
by our studies using shRNA knockdown or genetic deletion
of MK2, although MK2 cannot be uniquely targeted by
genetic approaches, as its knockdown results in simultaneous
destabilization of p38 (Figure 4a) (Kotlyarov et al., 2002;
Ronkina et al., 2007). Nevertheless, the MK2 silencing,
KO, and inhibitor studies all demonstrate a consistent pro-
tective phenotype with regard to maintenance of keratino-
cyte cell surface Dsg3 and spontaneous blistering, which
collectively support a role for the p38–MK2 signaling
pathway in PV pathogenesis. It is interesting that genetic loss
of MK2 and p38a in mouse epidermis may be more protec-
tive for suprabasal than superficial blistering (Figure 6 and
Supplementary Figure S1 online). This selective phenotype
was not observed with MK2 and p38 inhibitors, suggesting
that small-molecule inhibition of p38 and MK2 may be a more
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Figure 4. Silencing of MAPKAP (mitogen-activated protein kinase-activated protein) kinase 2 (MK2) expression prevents pemphigus vulgaris (PV) mAb-induced
loss of cell surface desmoglein 3 (Dsg3). (a) HaCaT cells that stably express MK2 short hairpin RNA (shRNA) show markedly reduced MK2 and p38 protein levels
compared with cells expressing control (Ctl) shRNA. Levels of histone H3 are shown as a loading control. (b) Immunofluorescence staining of HaCaT cells
expressing MK2 or control (Ctl) shRNA confirms knockdown of MK2 expression 72 hours after transduction. (c) shRNA silencing of MK2 expression decreases loss
of cell surface Dsg3 (shown in red) 16 hours after treatment with pathogenic PV mAb (P) and oxidative stress (H2O2). Bar¼ 20mm.
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effective method than genetic targeting for suppression of
blistering. The expression pattern of Dsg3 in the epidermis in
WT, MK2-KO, and p38-KO mice were similar, as determined
by direct immunofluorescence staining of Dsg3 (data not
shown). It is possible that the requirement for p38 or MK2 is
different downstream of Dsg3 and Dsg1 in the suprabasal
versus superficial epidermis (Spindler et al., 2011), e.g., due to
differential compensation by other proteins such as MK3,
MK5, or other p38 isoforms, or that the superficial epidermis is
more subject to frictional shear stress than the suprabasal
epidermis.
Consistent with our studies on p38, we observed
MK2-dependent and -independent mechanisms of blister
formation. In our models, Nikolsky skin fragility is p38 and
MK2 independent, evidenced in mice with a genetic deletion
of p38a in the epidermis (Mao et al., 2011), MK2-KO mice,
and WT mice treated with MK2 inhibitors (Figure 5). We
believe that this is the first step in disease pathology, reflecting
steric hindrance of Dsg adhesion by binding of pathogenic
anti-Dsg antibodies followed by mechanical shear stress. In
contrast, signaling-dependent pathology is evaluated in our
mouse models by spontaneous blistering, which occurs later
than Nikolsky skin fragility and is inhibited by genetic deletion
of MK2 or small-molecule inhibition of p38 and MK2
(Figure 6). These late events may reflect amplification of
pathology by activation of p38, which causes endocytosis of
multiple desmosomal molecules including Dsg3 and desmo-
collin 3, leading to desmosome disassembly (Mao et al.,
2009, 2011).
There are some discrepancies between our models and
studies using PV IgG. Blister formation by PV serum IgG, but
not a pathogenic mouse AK23 mAb, was blocked by p38
inhibition in human skin explants, which is primarily a test
of Nikolsky fragility (Saito et al., 2012). PV serum IgG may
have additional signaling-dependent pathogenic mechanisms
related to Dsg3 clustering, causing a more effective
disassembly of desmosomes (whereas mAbs primarily
deplete nondesmosomal Dsg3, with indirect effects on
desmosome disassembly; Mao et al., 2009). Induced blisters
after passive transfer of PV serum IgG to mice were also
blocked by p38 inhibition (Berkowitz et al., 2006). The latter
study used lower doses for histologic versus gross blister
evaluation, suggesting that the p38 dependence of induced
blisters may be dose dependent. Nevertheless, our models
using human anti-Dsg IgG4 mAbs offer the advantage of being
able to directly identify pathological effects because of anti-
Dsg antibodies in PV serum IgG and consistently reproduce
key aspects of disease pathology caused by PV serum IgG,
including activation of p38, Dsg endocytosis, and suprabasal
blisters in human and mouse skin.
In summary, our results suggest that MK2 is the major
pathological downstream effector of p38 signaling in pemphi-
gus. Future studies aim to establish a direct connection
between MK2 activation and the cell pathological effects of
PV autoantibodies, including potential effects on other des-
mosomal proteins such as desmocollin, desmoplakin, and
keratin. MK2 directly phosphorylates the actin-modulating
protein HSP27 (Stokoe et al., 1992), which is activated in
pemphigus (Berkowitz et al., 2007). In addition, MK2
phosphorylates keratins 18 and 20 in intestinal epithelial
cells (Menon et al., 2010). As collapse of the keratin
intermediate filament network is a prominent cytologic
finding in PV, it is possible that spontaneous blistering may
be directly linked to the regulation of the cytoskeletal network
by MK2.
Therapeutically, inhibition of MK2 activity represents a
more targeted strategy aimed to block the pathological
response of the skin to pemphigus autoantibodies, without
generally suppressing patients’ immunity. MK2-KO mice are
relatively resistant to endotoxic shock because of deficient
production of tumor necrosis factor-a, and this function is
partially redundant with MAPKAP kinase 3 (Kotlyarov et al.,
1999; Ronkina et al., 2007). Therefore, MK2 inhibition
may preserve systemic immunity while still inhibiting
the pathological effects of MK2 in skin keratinocytes.
Inhibition of MK2, either topically or systemically, may
represent a fast treatment option for PV during disease flare,
allowing time for immunosuppressive agents to decrease
pathogenic autoantibodies. Such interventions may be safer
than topical or oral corticosteroids, which are currently used
for rapid disease control.
MATERIALS AND METHODS
Antibodies and reagents
Antibodies included rabbit anti-p38, anti-MK2, anti-phospho-p38
(Thr180/Tyr182), anti-phospho-MK2 (Thr222, Cell Signaling
Technology, Danvers, MA), mouse anti-Dsg3 (5G11, Invitrogen,
Grand Island, NY), mouse anti-desmoplakin (BioDesign International,
Cincinnati, OH), mouse anti-keratin 14 (K14, Abcam, Cambridge,
MA), rabbit anti-histone H3 (Santa Cruz Biotechnology, Santa
Cruz, CA), horseradish peroxidase-–conjugated donkey anti-mouse
or -rabbit IgG (Jackson ImmunoResearch, West Grove, PA), Alexa
488–conjugated donkey anti-rabbit IgG, Alexa 488–conjugated goat
anti-mouse and rabbit IgG, and Alexa 594–conjugated goat
anti-mouse, rat, or rabbit IgG (Invitrogen).
PV IgG4 mAbs were produced as described, expressing the
(D31)2/29 pathogenic and (D31)12b/6 nonpathogenic variable regions
(also previously described as P1 and NP1 (Mao et al., 2009)) with an
IgG4 heavy chain (Payne et al., 2005, 2007).
Other reagents included p38 inhibitor (SB202190), hydrogen
peroxide, and puromycin (Sigma-Aldrich, St Louis, MO); MK2
inhibitor III, MK2 shRNA, and control shRNA lentiviral particles
(Santa Cruz Biotechnology).
Cell culture and treatments
PHEKs were obtained from the Penn Skin Disease Research Center
(Philadelphia, PA) and cultured as described (Mao et al., 2009, 2011).
For p38 or MK2 inhibition assays, cells were treated with 0–2mM
SB202190 or 0–5mg ml 1 MK2 inhibitor, followed by 200mg ml 1
PV mAbs or 200mM H2O2. HaCaT cells were maintained in 50%
defined keratinocyte–serum free medium/50% DMEM containing
10% fetal bovine serum and penicillin/streptomycin.
Immunofluorescence
Immunofluorescence was performed as described for PHEKs
(Mao et al., 2009) and mouse skin (Mao et al., 2011).
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Subcellular fractionation/immunoblotting
After incubation with PV mAbs, PHEKs were chilled on ice and
washed with ice-cold phosphate-buffered saline. Cells were harvested
in ice-cold phosphate-buffered saline by centrifugation at 2,500 g for
1 minute at 4 1C, then lysed in buffer containing 10 mM Hepes
(pH 7.6), 0.4 mM CaCl2, 10 mM KCl, 1.5 mM MgCl2, 1 mM dithiothrei-
tol, 0.5 mM phenylmethylsulfonylfluoride, and 10mg ml 1 aprotinin
and leupeptin on ice for 10 minutes. Lysates were passaged 20 times
through a 26-G insulin syringe, followed by centrifugation at 7,200 g
for 1 minute at 4 1C. The supernatant (cytoplasmic fraction) was
removed, and the remaining nuclear pellet was washed and
solubilized in Laemmli sample buffer. Triton X-100 cell fractionation
and immunoblotting were performed as described previously
(Mao et al., 2011).
RNA interference
MK2 and control lentiviral shRNA were used to infect HaCaT cells,
according to the manufacturer’s protocols. At 72 hours after transduc-
tion, cells were selected with media containing 5mg ml 1 puromycin.
Transduced cells were treated with 50mg ml 1 PV mAbs or 100mM
H2O2 for 24 hours before analysis.
Neonatal mouse passive transfer
p38 fl/fl;þ /þ (WT) or p38 fl/fl;K14cre/þ (KO) mice (Mao et al.,
2011) or MK2 KO mice (Kotlyarov et al., 1999) and wild-type
littermate controls were used for passive transfer studies. Newborn
mice (1–3 days, 1.2–2.5 g) were injected intradermally with 25mg
purified PV monoclonal IgG4, þ /–intradermal injection of p38 or
MK2 inhibitor 2 hours before, and killed 16–18 hours after the last
injection for evaluation. Skin sections were processed as described
previously (Mao et al., 2011). Histology scores on serial sections were
quantified as described previously (Spindler et al., 2013).
Histology/immunohistochemistry
Formalin-fixed, paraffin-embedded mouse skin sections were stained
with hematoxylin and eosin according to standard procedures.
Human pemphigus skin sections were obtained from the Penn Skin
Disease Research Center Tissue Bank. Immunohistochemical analysis
was performed to evaluate MK2 activation as described (Mao et al.,
2011), incubating a rabbit anti-phospho-MK2 antibody (1:500) with
sections overnight at 4 1C, followed by peroxidase-conjugated donkey
anti-rabbit IgG for 1 hour at room temperature.
Statistical analysis
Fisher’s exact test (Figures 5a and d and 6a and d), Wilcoxon
rank-sum test (Figures 5f and 6c), and Kruskal–Wallis test with Dunn’s
post hoc multiple comparisons analysis (Figures 5c and 6f) were
performed to identify significant differences. Po0.05 was considered
significant.
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